Related Experiment Video
Updated: Jul 5, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas.
Dipti Talaulikar1, Ayesha Choudhury, Bruce Shadbolt
1Department of Haematology, ACT Pathology, The Canberra Hospital, Garran, Australia.
Leukemia & Lymphoma
|May 9, 2008
Summary
Lymphocytopenia, a low lymphocyte count, is common at diagnosis in diffuse large B-cell lymphoma (DLBCL). This condition significantly predicts poor survival outcomes, independent of the International Prognostic Index (IPI).
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Lymphocytopenia is linked to adverse outcomes in hematological malignancies.
- Recent findings suggest lymphocytopenia is associated with poor prognosis in diffuse large B-cell lymphoma (DLBCL).
Purpose of the Study:
- To determine the incidence of lymphocytopenia at diagnosis in DLBCL patients.
- To confirm lymphocytopenia's significance as an independent prognostic factor, especially concerning the International Prognostic Index (IPI).
Main Methods:
- Retrospective analysis of medical and laboratory records from 165 DLBCL patients.
- Correlation of lymphocyte counts with overall survival.
- Determination of prognostic significance independent of the IPI using Cox regression.
Main Results:
- Lymphocytopenia (lymphocyte count ≤1x10(9)/L) was observed in 35.8% of patients.
- Patients with lymphocytopenia had significantly shorter overall survival (3.4 years vs. 10.3 years, p=0.002).
- Cox regression confirmed lymphocytopenia as a prognostic marker independent of the IPI.
Conclusions:
- Lymphocytopenia at diagnosis is a frequent finding in DLBCL.
- Lymphocytopenia is a significant adverse prognostic factor for overall survival in DLBCL.
- The prognostic value of lymphocytopenia is independent of the established IPI in DLBCL.
